血清apoA1水平与冠心病患者左室收缩功能的关系

王丽君; 郜珊珊

doi:10.13201/j.issn.1001-1439.2021.11.004

血清apoA1水平与冠心病患者左室收缩功能的关系

王丽君^1,2,
郜珊珊^1, ,

- 1. 西安交通大学第一附属医院心内科(西安, 710061);
- 2. 陕西省分子心脏病学重点实验室
基金项目:
国家自然科学基金青年基金项目(No.81700447)

陕西省自然科学基础研究计划项目(No:2019JQ955)

西安交通大学第一附属医院临床研究基金(No:XJTU1AF-CRF-2018-010)

详细信息

通讯作者: 郜珊珊,E-mail:gaoshanshj@163.com

中图分类号: R541.4

收稿日期: 2021-06-30

Relationship between serum apoA1 levels and left ventricular systolic function in patients with coronary artery disease

WANG Lijun^1,2,
GAO Shanshan^1, ,

- 1. Department of Cardiology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China;
- 2. Key Laboratory of Molecular Cardiology in Shaanxi Province

More Information

Corresponding author: GAO Shanshan, E-mail: gaoshanshj@163.com

Received Date: 30 June 2021

摘要

摘要: 目的:观察和分析冠心病患者血清载脂蛋白A1(apoA1)与左室收缩功能之间的关系。方法:纳入经冠状动脉造影明确诊断为冠心病的患者共计3402例,按照血清apoA1水平的三分位数将患者分为高中低3组,比较各组之间患者基线资料和生化指标的差异,以及心力衰竭亚型在各组之间的分布;Logistic回归分析评估血清apoA1水平与左室收缩功能之间的关系。结果:高apoA1组的左室收缩功能较低apoA1组更好[左室射血分数(LVEF)(63.63±9.23)%∶(59.62±11.33)%,P<0.001];高apoA1组的射血分数降低性心力衰竭(HFrEF)患者比例也显著降低(1.5%∶5.2%,P<0.001)。Logistic回归分析显示在调整所有基线差异后,血清apoA1水平是重度心功能不全的保护性因素(P<0.001)。结论:血清apoA1水平与冠心病患者左室收缩功能相关,是冠心病患者心功能不全的保护性预测因子。
- 载脂蛋白A1 /
- 左室收缩功能 /
- 左室射血分数 /
- 冠心病
Abstract: Objective: To investigate and evaluate the relationship between serum apolipoprotein A1(apoA1) level and Left ventricular systolic function in patients with coronary artery disease.Methods: A total of 3402 patients who underwent coronary angiography were diagnosed as coronary artery disease, and then divided into three groups according the serum apoA1 level tertiles. Patients' baseline characteristics and biochemical parameters were recorded and analyzed. We further evaluated the relationship among the serum apoA1 and various heart failure subtypes and left ventricular systolic function.Results: The left ventricular systolic function in the highest apoA1 group was better than in the low apoA1 group[LVEF(63.63±9.23)%vs(59.62±11.33)%, P<0.001], and there was a significant positive correlation between the serum apoA1 level and LVEF(r=0.122, P<0.001); The patients in highest apoA1 group also had lower proportion of heart failure with reduced ejection fraction(1.5% vs 5.2%, P<0.001). Logistic regression analysis showed that after adjusting for all baseline differences, higher apoA1 level remained significantly negatively associated with worse left ventricular systolic function.Conclusion: Serum apoA1 level is significantly positively associated with LVEF in patients with coronary heart disease, and it may be an independent protective predictor of left ventricular systolic function in patients with coronary heart disease.
- apolipoprotein A1 /
- left ventricular systolic function /
- left ventricular ejection fraction /
- coronary artery disease

HTML全文

参考文献(15)

[1]	Jabbar A,Ingoe L,Junejo S,et al.Effect of levothyroxine on left ventricular ejection fraction in patients with subclinical hypothyroidism and acute myocardial infarction:a randomized clinical trial[J].JAMA,2020,324(3):249-258.
[2]	Jiménez-Blanco M,Cordero D,Zamorano JL.Left ventricular ejection fraction…What else?[J].Cardiol J,2020,27(1):6-7.
[3]	Branca L,Sbolli M,Metra M,et al.Heart failure with mid-range ejection fraction:pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines[J].ESC Heart Fail,2020,7(2):381-399.
[4]	Taqueti VR,Solomon SD,Shah AM,et al.Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction[J].Eur Heart J,2018,39(10):840-849.
[5]	Chen W,Wu Y,Lu Q,et al.Endogenous ApoA-I expression in macrophages:A potential target for protection against atherosclerosis[J].Clin Chim Acta,2020,505:55-59.
[6]	Gombos T,Förhécz Z,Pozsonyi Z,et al.Long-term survival and apolipoprotein a1 level in chronic heart failure:interaction with tumor necrosis factor α-308 G/A polymorphism[J].J Card Fail,2017,23(2):113-120.
[7]	Wedel H,McMurray JJ,Lindberg M,et al.Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure(CORONA):incremental value of apolipoprotein A-1,high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide[J].Eur J Heart Fail,2009,11(3):281-291.
[8]	Iwaoka M,Obata JE,Abe M,et al.Association of low serum levels of apolipoprotein A-I with adverse outcomes in patients with nonischemic heart failure[J].J Card Fail,2007,13(4):247-253.
[9]	王华,梁延春.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[10]	Gerber Y,Weston SA,Enriquez-Sarano M,et al.Atherosclerotic burden and heart failure after myocardial infarction[J].JAMA Cardiol,2016,1(2):156-162.
[11]	Ertek S.High-density lipoprotein(HDL)dysfunction and the future of HDL[J].Curr Vasc Pharmacol,2018,16(5):490-498.
[12]	苏广胜,付茜,庞文跃.载脂蛋白B/载脂蛋白A1比值与青年冠心病患者冠状动脉病变严重程度的研究[J].临床心血管病杂志,2021,37(7):663-667.
[13]	Gkouskou KK,Ioannou M,Pavlopoulos GA,et al.Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis[J].Oncogene,2016,35(19):2496-2505.
[14]	Gordon SM,Hofmann S,Askew DS,et al.High density lipoprotein:it's not just about lipid transport anymore[J].Trends Endocrinol Metab,2011,22(1):9-15.
[15]	Wu TT,Zheng YY,Yang YN,et al.Age,sex,and cardiovascular risk attributable to lipoprotein cholesterol among chinese individuals with coronary artery disease:a case-control study[J].Metab Syndr Relat Disord,2019,17(4):223-231.